Last reviewed · How we verify
NCT06180031: Peng Block
Effect of Adding Magnesium Sulphate in Pericapsular Nerve Group Block
Phase 2, PHASE3 trial testing Pericapsular nerve group block using bupivicaine and magnesium sulphate in Hip Fractures in 62 participants. Status unknown.
1 January 2025
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 62 |
| Start date | 1 January 2024 |
| Primary completion | 1 January 2025 |
| Estimated completion | 30 March 2025 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Pericapsular nerve group block using bupivicaine and magnesium sulphate — full drug profile →
Conditions studied
- Hip Fractures — all drugs for Hip Fractures →
Sponsor
Assiut University
Who can join
Adults 18 to 65, any sex, with Hip Fractures. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Our aim will be to compare the analgesic efficacy and safety of magnesium sulphate as an adjuvant to bupivacaine in pericapsular nerve group block in Hip joint surgeries. * Our primary outcome of the study: total amount of postoperative morphine consumption in the first 24h postoperative. * Our secondary outcome of the study: mean arterial blood pressure, heart rate, respiratory rate, adverse effects, block related complication, sedation score (by Ramsay sedation scale) and pain score (by Visual Analog Scale)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06180031
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hip Fractures
Currently open trials in the same condition.
- NCT07239817 — PENG Block + LIA For Endoprosthesis Surgery With Anterior Approach · NA · recruiting
- NCT07002723 — Effects of Esketamine Combined With Dexmedetomidine on Postoperative Sleep Quality · NA · recruiting
- NCT06893406 — Cervical Myelopathy in Hip Fracture Patients · NA · recruiting
- NCT06565910 — Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG) · Phase 4 · recruiting
- NCT06455813 — What Laxative Should be Used After Hip Fracture Surgery? · Phase 4 · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06180031 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 22 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06180031.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing